Short-course vaginal cuff brachytherapy (VCB) is noninferior to standard regimens for short-term quality of life in people with early-stage endometrial cancer, according to a study published online ...

Uterine cancer (also known as endometrial cancer) is the fourth most common cancer women in the U.S. are diagnosed with. It ...

GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...

Endometrial cancer isn’t talked about much as much as it should be. It’s the most common cancer of the female reproductive organs in the U.S. and more than 69,000 people in the U.S. are diagnosed with ...

Endometriosis, a prevalent gynecological condition, is characterized by the growth of endometrial-like tissues outside the ...

GSK PLC on Monday said the European Commission has expanded approval for its drug Jemperli, in combination with chemo ... Subscribe now to see this Premium News article from Alliance News ...

Endometrial cancer starts in the tissue that lines your uterus. If the cancer is platinum-resistant, platinum-based chemotherapy drugs will not work well to kill it or stop it from returning after ...

Jemperli (Dostarlimab): GlaxoSmithKline Jemperli (dostarlimab) is an anti-PD-1 monoclonal antibody developed by GlaxoSmithKline that has been approved for use in advanced or recurrent endometrial ...

The EMA’s acceptance of the prefilled syringe follows the European Commission’s (EC) approval of GSK’s Jemperli, combined with chemotherapy for the treatment of advanced or recurrent endometrial ...

Used to treat advanced or recurrent endometrial cancer, Jemperli Dostarlimab, presents an opportunity to enhance the immune response against cancer cells when combined with chemotherapy. Get Your Free ...

Used to treat advanced or recurrent endometrial cancer, Jemperli Dostarlimab, presents an opportunity to enhance the immune response against cancer cells when combined with chemotherapy.